Teacher Retirement System of Texas Trims Stock Position in Guardant Health, Inc. $GH

by · The Cerbat Gem

Teacher Retirement System of Texas decreased its position in Guardant Health, Inc. (NASDAQ:GH – Free Report) by 9.8% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 18,339 shares of the company’s stock after selling 1,992 shares during the period. Teacher Retirement System of Texas’ holdings in Guardant Health were worth $954,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of GH. IFP Advisors Inc raised its position in Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares in the last quarter. Signaturefd LLC increased its stake in shares of Guardant Health by 50.5% during the second quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after buying an additional 213 shares during the period. FNY Investment Advisers LLC bought a new stake in shares of Guardant Health in the second quarter valued at about $62,000. SVB Wealth LLC purchased a new stake in Guardant Health in the first quarter worth about $54,000. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new stake in Guardant Health in the first quarter worth about $97,000. Institutional investors own 92.60% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on the stock. Wells Fargo & Company assumed coverage on shares of Guardant Health in a research report on Monday, September 22nd. They set an “overweight” rating and a $72.00 target price on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Guardant Health from $60.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, September 25th. Mizuho set a $100.00 price objective on shares of Guardant Health in a research note on Thursday, October 30th. Wolfe Research upgraded Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price for the company in a report on Thursday, September 25th. Finally, Evercore ISI lifted their price target on Guardant Health from $68.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $77.14.

Check Out Our Latest Report on Guardant Health

Guardant Health Trading Up 1.3%

NASDAQ GH opened at $96.25 on Friday. The firm’s fifty day simple moving average is $66.93 and its two-hundred day simple moving average is $54.59. The firm has a market capitalization of $12.13 billion, a P/E ratio of -29.98 and a beta of 1.56. Guardant Health, Inc. has a 12-month low of $28.20 and a 12-month high of $100.22.

Guardant Health (NASDAQ:GH – Get Free Report) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.26). The firm had revenue of $265.20 million during the quarter, compared to analysts’ expectations of $235.72 million. During the same period last year, the firm earned ($0.88) earnings per share. Guardant Health’s quarterly revenue was up 38.5% on a year-over-year basis. Guardant Health has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Insider Transactions at Guardant Health

In other Guardant Health news, CEO Helmy Eltoukhy sold 300,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the sale, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at approximately $126,242,015.55. The trade was a 12.38% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Medina Manuel Hidalgo sold 2,165 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the transaction, the director directly owned 851 shares of the company’s stock, valued at approximately $46,090.16. This represents a 71.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 302,691 shares of company stock worth $17,984,628 in the last 90 days. Insiders own 6.10% of the company’s stock.

Guardant Health Profile

(Free Report)

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Featured Articles